常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.39/0.67
|
|
企业价值
124.06M
|
| 资产负债 |
|
每股账面净值
0.39
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/07 13:27 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in itsPhase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |

1.41 
